ScreenerHero

LONN Lonza Group AG

SWX · CH · Healthcare · Diagnostics & Research · lonza.com
573.60CHF+1.41%Mkt Cap: 45.82B $P/E: 38.09

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc Common Stock
$242.11BUSDP/E 35.5
DHR
Danaher Corporation Common Stock
$150.48BUSDP/E 38.2
NTRA
Natera, Inc. - Common Stock
$59.15BUSD
A
Agilent Technologies, Inc. Common Stock
$47.30BUSDP/E 33.1
IQV
IQVIA Holdings, Inc. Common Stock
$42.50BUSDP/E 32.2
WAT
Waters Corporation Common Stock
$41.75BUSDP/E 107.4
ILMN
Illumina, Inc. - Common Stock
$41.23BUSDP/E 50.8
IDXX
IDEXX Laboratories, Inc. - Common Stock
$40.89BUSDP/E 36.4
MTD
Mettler-Toledo International, Inc. Common Stock
$29.78BUSDP/E 34.0
DGX
Quest Diagnostics Incorporated Common Stock
$25.75BUSDP/E 25.0
LH
Labcorp Holdings Inc. Common Stock
$25.02BUSDP/E 25.5
GH
Guardant Health, Inc. - Common Stock
$23.86BUSD
RVTY
Revvity, Inc. Common Stock
$16.91BUSDP/E 72.5
MEDP
Medpace Holdings, Inc. - Common Stock
$16.73BUSDP/E 35.2
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
CRL
Charles River Laboratories International, Inc. Common Stock
$13.85BUSD
ICLR
ICON plc - Ordinary Shares
$12.50BUSDP/E 249.3
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V. Common Shares
$9.24BUSDP/E 22.7
GRAL
GRAIL, Inc. - Common Stock
$6.40BUSD

Key Statistics

Company
Market Cap45.82B USD
Enterprise Value49.28B USD
Revenue (TTM)7.84B USD
Gross Profit2.64B USD
Net Income (TTM)-313.86M USD
Revenue/Share98.33 CHF
Last Price573.60 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.1K
CountryCH
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)38.09
P/E (Forward)25.64
PEG1.02
EV/EBITDA18.07
EV/Revenue6.28
P/S5.75
P/B4.86
EPS (TTM)15.09
EPS (Forward)22.06
52W Range
454.6085% of range594.60
52W High594.60 CHF
52W Low454.60 CHF
Profitability
Gross Margin35.35%
Oper. Margin23.41%
EBITDA Margin34.78%
Profit Margin-4.21%
ROE-3.48%
ROA-1.54%
Growth
Revenue Growth11.20%
Earnings Growth39.20%
Cash Flow & Leverage
Operating CF1.32B USD
CapEx (TTM)1.57B USD
FCF Margin-22.81%
FCF Yield-3.90%
Net Debt4.20B USD
Net Debt/EBITDA1.54
Balance Sheet
Debt/Equity0.57
Current Ratio1.66
Quick Ratio0.59
Book Value/Sh116.37 CHF
Cash/Share6.98 CHF
Dividends
Fwd Div Rate5.00 CHF
Trail. Div Rate5.00 CHF
Div. Yield0.88%
5Y Avg Yield0.66%
Payout Ratio32.28%
Ex-Div DateMay 12, 2026
Pay DateMay 15, 2025
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)688.17 CHF
Upside (mean)+20.0%
Target Range550.00 CHF – 835.00 CHF
550.00+20.0% to mean835.00
# Analysts23
Ownership
Shares Out.69.84M
Float69.74M
Insiders0.09%
Institutions58.74%
Technical
SMA 50566.43 (+1.3%)
SMA 200530.75 (+8.1%)
Beta0.84
S&P 52W Chg14.58%
Avg Vol (30d)126.10K
Avg Vol (10d)102.38K
Technical Indicators
RSI (14)51.5
MACD2.3373
MACD Signal0.1943
MACD Hist.+2.1431
BB Upper588.63 CHF
BB Middle555.17 CHF
BB Lower521.71 CHF
BB Width12.05%
ATR (14)11.89 CHF
Vol Ratio (20d)0.70x